FDA Unveils Considerations for Rescinding Breakthrough Therapy Designation | Cooley LLP
On June 24, 2022, the US Food and Drug Administration issued a draft guidance document on the Considerations for Rescinding Breakthrough Therapy Designation. The guidance explains how...
Source: jdsupra.com